Conference Coverage

Study finds AD accounts for hundreds of thousands of annual ED visits


 

REPORTING FROM AAD 18

– A new study finds that primary diagnoses of atopic dermatitis (AD) are made hundreds of thousands of times in United States emergency departments each year.

The numbers appear to be rising along with costs, researchers reported, and there are signs of disparities, with poorer people more likely to have an ED visit with a primary diagnosis of AD. The study was presented in a poster at the annual meeting of the American Academy of Dermatology.

Dr. Jonathan Silverberg of Northwestern University, Chicago

Dr. Jonathan Silverberg

“Access to outpatient dermatologic care needs to be improved,” study investigator Jonathan I. Silverberg, MD, PhD, of the department of dermatology, Northwestern University, Chicago, said in an interview. “Since AD is a chronic disorder that can be managed in the outpatient setting most of the time, it is likely that improved outpatient access and care and tighter control of AD would result in fewer [ED] visits and a considerable costs savings in the long run.”

He and his coauthor, Lauren Kwa, also with the department of dermatology at Northwestern, conducted the analysis to better understand the role of AD in emergency care. “Many AD patients experience severe, unpredictable flares and worsening chronic disease that warrant urgent treatment,” Dr. Silverberg said. “However, patients typically don’t have instant access to outpatient dermatological care and may be forced to turn to the urgent care setting.”

Pages

Recommended Reading

Mobile Medical Apps for Patient Education: A Graded Review of Available Dermatology Apps
MDedge Dermatology
VIDEO: Off-label dupilumab finding a home in pediatric AD
MDedge Dermatology
‘Cutting for Stone’ author closes out this year’s AAD plenary session
MDedge Dermatology
Late-breaking research presented at AAD on Saturday February 17
MDedge Dermatology
VIDEO: Select atopic dermatitis patients need patch testing
MDedge Dermatology
Upadacitinib calms itch, clears skin in moderate to severe atopic dermatitis
MDedge Dermatology
Anti–IL-33 antibody stakes a first-in-class claim on moderate to severe atopic dermatitis
MDedge Dermatology
VIDEO: With new therapies available, it’s the ‘decade of eczema,’ researcher says
MDedge Dermatology
Dual kinase inhibitor performs well in its first safety, efficacy study for atopic dermatitis
MDedge Dermatology
VIDEO: Cannabinoids in dermatology
MDedge Dermatology